These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22932290)

  • 21. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency.
    Schiel R; Franke S; Busch M; Müller A; Fleck C; Müller UA; Braun A; Stein G
    Eur J Med Res; 2003 Jul; 8(7):283-91. PubMed ID: 12911864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers.
    Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K
    Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
    Busch M; Franke S; Stein G; Wolf G;
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated Serum Pentosidine and Decreased Serum IGF-I Levels are Associated with Loss of Muscle Mass in Postmenopausal Women with Type 2 Diabetes Mellitus.
    Tanaka K; Kanazawa I; Sugimoto T
    Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):163-6. PubMed ID: 26575120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS.
    Seftel AD; Vaziri ND; Ni Z; Razmjouei K; Fogarty J; Hampel N; Polak J; Wang RZ; Ferguson K; Block C; Haas C
    Urology; 1997 Dec; 50(6):1016-26. PubMed ID: 9426743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Determinants of bone quality and strength independent of bone remodeling].
    Saito M; Marumo K
    Clin Calcium; 2016 Jan; 26(1):29-41. PubMed ID: 26728528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes.
    Yamamoto M; Yamaguchi T; Nawata K; Yamauchi M; Sugimoto T
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1277-84. PubMed ID: 22337915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone fragility in type 2 diabetes mellitus.
    Yamaguchi T
    World J Orthop; 2010 Nov; 1(1):3-9. PubMed ID: 22474621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age.
    Creecy A; Uppuganti S; Unal M; Clay Bunn R; Voziyan P; Nyman JS
    Bone; 2018 May; 110():204-214. PubMed ID: 29438824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Lifestyle-related disease associated osteoporosis: Diabetes].
    Yamamoto M
    Clin Calcium; 2015 Sep; 25(9):1319-27. PubMed ID: 26320532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Poor bone quality in diabetes and arterioscelerosis].
    Saito M
    Clin Calcium; 2009 Sep; 19(9):1257-68. PubMed ID: 19721196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.
    Horie K; Miyata T; Maeda K; Miyata S; Sugiyama S; Sakai H; van Ypersole de Strihou C; Monnier VM; Witztum JL; Kurokawa K
    J Clin Invest; 1997 Dec; 100(12):2995-3004. PubMed ID: 9399945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus.
    Botushanov NP; Orbetzova MM
    Folia Med (Plovdiv); 2009; 51(4):12-7. PubMed ID: 20232652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diabetic paradox: Bone mineral density and fracture in type 2 diabetes.
    Botella Martínez S; Varo Cenarruzabeitia N; Escalada San Martin J; Calleja Canelas A
    Endocrinol Nutr; 2016 Nov; 63(9):495-501. PubMed ID: 27481443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients.
    Chen H; Li X; Yue R; Ren X; Zhang X; Ni A
    Diabetes Res Clin Pract; 2013 May; 100(2):272-6. PubMed ID: 23522918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties.
    Karim L; Bouxsein ML
    Bone; 2016 Jan; 82():21-7. PubMed ID: 26211993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic bone disease. Low turnover osteoporosis related to decreased IGF-I production.
    Bouillon R
    Verh K Acad Geneeskd Belg; 1992; 54(4):365-91; discussion 391-2. PubMed ID: 1466160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.
    Beisswenger PJ; Moore LL; Brinck-Johnsen T; Curphey TJ
    J Clin Invest; 1993 Jul; 92(1):212-7. PubMed ID: 8325987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.